NRAS G12D
4 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (NCT04853017) | Elicio Therapeutics | 2021-10-04 |
| Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma (NCT07083479) | Elicio Therapeutics |
Track NRAS G12D automatically
Every clearance here is in the API, with alerts when new ones post.